Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aldeyra Therapeu
(NQ:
ALDX
)
3.910
-0.020 (-0.51%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
January 04, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
55 Biggest Movers From Yesterday
December 22, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher
December 21, 2021
Toward the end of trading Tuesday, the Dow traded up 1.52% to 35,463.11 while the NASDAQ rose 2.10% to 15,295.45. The S&P also rose, gaining 1.55% to 4,638.74. The U.S. has...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 21, 2021
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide
December 21, 2021
Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The S&P also rose, gaining 0.80% to 4,605.08. The U.S. has the...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
December 21, 2021
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...
Via
Benzinga
Stocks Set to Snap Selloff, Dow Eyes Triple-Digit Pop
December 21, 2021
The major benchmarks look set to snap their three-day losing streak today, as investors reassess their anxieties over the fast-spreading omicron variant.
Via
Talk Markets
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 21, 2021
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 21, 2021
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
10 Biggest Price Target Changes For Tuesday
December 21, 2021
B of A Securities lifted the price target on Micron Technology, Inc. (NASDAQ:
Via
Benzinga
26 Stocks Moving in Tuesday's Pre-Market Session
December 21, 2021
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains...
Via
Benzinga
Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study
December 21, 2021
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial...
Via
Benzinga
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
December 20, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Upcoming Conferences
November 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
November 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 02, 2021
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%...
Via
Benzinga
Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance
November 02, 2021
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 02, 2021
Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo...
Via
Benzinga
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
November 02, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics (ALDX) Q3 2021 Earnings Call Transcript
October 29, 2021
ALDX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
October 28, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
October 21, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 09, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
September 02, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics (ALDX) Q2 2021 Earnings Call Transcript
August 07, 2021
ALDX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
August 05, 2021
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
August 04, 2021
The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.